Introduction
G protein-coupled receptors (GPCRs) constitute the largest protein family of cell surface receptors, and they mediate a variety of signaling processes. Over the last 30 years, many researchers have identified that GPCRs can form dimeric and higher-order oligomers in natural tissues [1, 2] . In comparison with the constituting receptors, GPCR heteromers, which have different characteristics, are important for the understanding of receptor function and pharmacology. As a result, bivalent ligands are currently being developed as a promising strategy for drug discovery [3, 4] . The adenosine A 1 and dopamine D 1 receptors belong to the superfamily of GPCRs. Evidence for the existence of A 1 R and D 1 R heteromers has been presented and is based on immunoprecipitation and double immunolabeling experiments [5] . There are two subtypes of striatal GABAergic efferent neurons, projecting to the thalamus across two distinct pathways: the striato pallidal neurons (indirect pathway) and the striatonigrostriatoentopeduncular neurons (direct pathway). Evidence indicates that A 1 R and D 1 R are coexpressed in the basal ganglia and prefrontal cortex, which are particularly involved in the direct pathway [6] . In rat models of Parkinson's disease, the motor activating effects of the D 1 agonist, SKF38393, were enhanced by the A 1 receptor antagonist [7] . This synergistic mechanism may provide some insight into the design of novel agents for the treatment of Parkinson's disease and neuropsychiatric disorders based on the pharmacological properties of the A 1 -D 1 heteromeric complex [5] . Although heteromerization was reported in native tissues, there is no direct evidence to prove the existence of A 1 -D 1 receptor heterodimerization. A 1 -D 1 bivalent ligands could be important research tools to detect heterodimerization and further explore the biological functions of A 1 -D 1 receptor het-erodimers.
Bivalent ligands are molecules that consist of two pharmacophores linked by a spacer [8] . Recently, synthesis and biological investigations of bivalent ligands were described to target serotonin [9] , muscarinic [10] , opioid [11] and other receptors. Rafael Franco and Miriam Royo designed bivalent ligands targeting A 2A R-D 2 R heterodimerization, which contained a D 2 R agonist, a A 2A R antagonist and their corresponding monovalent control compounds. Their results indicated that the existence of A 2A R-D 2 R heterodimerization and a simultaneous interaction of bivalent ligands with both receptors [12] . We designed and synthesized a group of bivalent ligands containing a D 1 R agonist and a A 1 R antagonist linked by different lengths of PEG linkers. The binding properties of these compounds were determined by radioligand binding studies in membrane preparations from brain striatum. FRET experiments were performed to test if these bivalent ligands can promote the formation of A 1 R and D 1 R heterodimers ( Figure 1 ).
Materials and methods

Chemistry
Compound design A 1 -D 1 bivalent ligands were designed by combining two pharmacophoric entities with different lengths of linkers. First, compound 1, a naphthylxanthine derivative, was chosen as the A 1 antagonist pharmacophore. Then, SKF38393, a 1-aryl-3-benzazepine analog that displays high binding affinity at the D 1 receptor, was selected as the D 1 agonist pharmacophore. Structure-activity relationship indicated that the N-3 site of compound 1 and 4' site of SKF38393 are not active sites [13] [14] [15] [16] . Thus, linkers were introduced at these sites to combine the A 1 antagonist and D 1 agonist pharmacophores.
Polyethylene glycol (PEG) is widely used due to its low toxicity, excellent aqueous solubility and low antigenicity. Recently, Kiessling et al found that an unexpected enhancement in the biological activity of a GPCR ligand was induced by a polyethylene glycol substitute [17] . Considering the fact that PEG has a moderate ΔS tor (the entropy associated with torsional motions about a single bond) [18] , PEG was chosen as the linker for the selected pharmacophores. Recently, Gmeiner et al reported the synthesis and biological investigation of bivalent ligands for D 2 -like receptors. Bivalent ligands, linked by 5-8 oligoethylene glycol units, showed up to a 70-fold increase of D 3 binding affinity compared to monovalent ligand compounds [19] . As a result, we designed bivalent ligands linked by 4 and 6 oligoethylene glycol units. We also synthesized the corresponding monovalent ligand compounds for the A 1 antagonist as a control to determine whether the bivalent ligands showed improved affinity for the A 1 receptor compared to the monovalent ligand controls. In 1991, Neumeyer et al synthesized the derivative of SKF38393 to identify effective fluorescent probes. However, coupling of the large group to the 4' site of SKF38393 resulted in a considerable loss of affinity [20] . As a result, we did not synthesize the corresponding monovalent ligand compounds for the D 1 antagonist as a control.
Preparation of the bivalent ligands and their monovalent ligands
Bivalent ligands linked by PEG chains were synthesized by the route demonstrated in Scheme 1. Commercially available polyethylene glycol was easily converted to compound 2a-2b using acrylonitrile via the Michael addition reaction. Reduction of compound 2a-2b with borane produced the compound 3a-3b.
The synthesis of the common intermediate, compound 4, has previously been described [13] . Treatment of compound 4 with ethyl 4-bromobutanoate produced compound 5. Then, compound 5 was heated in 20% NaOH (aq), followed by ring closure, to generate compound 6. Compound 6 was coupled with 3a-3b in the presence of PyBop/DIPEA in DMF to yield 7a-7b.
Commercially available nitroacetophenone was transformed into compound 8 using a catalytic amount of Lewis acid. The reaction of 8 with NaBH 4 produced compound 9. Compound 9 and commercially available 3,4-dimethoxy phenylethylamine were heated at reflux in THF to yield compound 10. Compound 10 was heated in PPA, followed by ring closure, to produce the cyclization compound 11. The reaction of 11 with iron powder generated compound 12. The addition of a Nosyl group to 12 in the presence of basic conditions yielded compound 13. Compound 13 was converted to 14 via a Mitsunobu reaction. Deprotection of compound 14 with BBr 3 at -78 °C produced compound 15 without future purification. The addition of a MOM group to 15 under basic conditions produced compound 16. Compound 17 was easily obtained from 16 via an ester hydrolysis reaction.
Compounds 18a-18b were obtained from 17 and 7a-7b using standard peptide synthesis procedures, with EDCI/ HOBt as the catalytic coupling agents. Removal of the Nosyl group in 18a-18b, in the presence of K 2 CO 3 and PhSH, yielded compound 19a-19b. Deprotection of compound 19a-19b with BBr 3 at -78 o C gave the target compound 20a-20b (Scheme 1). Monovalent ligands were synthesized, and the route is demonstrated in Scheme 2. Compounds 21a-21b were obtained using hexanoic acid, and 7a-7b were obtained using standard peptide synthesis procedures, with EDCI/HOBt as the catalytic coupling agents. When the water bath was finished, the reaction buffer was immediately filtered using a Brandel 24-well cell collector and GF/B filter to stop the reaction. The filter was washed three times with ice-cold 50 mmol/L Tris-HCl buffer (pH=7.4). After the filter was dry and transferred to a 0.5 mL EP, flashing liquid was added and a MicroBeta2 porous plate was used to measure the radiation activity. The equation for calculating the inhibition rate was as follows:
Reagents and conditions
Inhibition rate (%)=100-(cpm sample -cpm non-specific binding )/ (cpm total binding -cpm non-specific binding )×100 Non-linear regression implemented using GraphPad Prism 4.0 (GraphPad Software Inc) was used to calculate the IC 50 .
Measurement of FRET efficiency in HEK293 cells
FRET technology detects protein-protein interactions in live cells with high sensitivity [21] . FRET occurs when a donor chromophore, initially in its electronic excited state, transfers energy to a nearby acceptor chromophore (10- FRET efficiency=F 440/520 /F 440/470 . F 440/520 was the fluorescence intensity detected through channel 1, and F 440/470 was the fluorescence intensity detected through channel 2. The excitation wavelength for CFP was 440 nm and for YFP was 520 nm, and 470 nm was the emission wavelength for CFP.
Ligand docking studies Homology models of the adenosine A 1 receptor and dopamine D 1 receptor were built using Modeller 9.10. The model of the A 1 receptor was constructed using the crystal structure of the adenosine A 2A receptor (PDB code: 3EML) as a template [22] . The model of the D 1 receptor was constructed using multiple templates from the crystal structures of Rhodopsin (PDB code: 1U19) [23] , the β 2 adrenergic receptor (PDB code: 2RH1) [24] , the histamine H 1 receptor (PDB code: 3RZE) [25] , the S1P1 receptor (PDB code: 3V2Y) [26] , and the dopamine D 3 receptor (PDB code: 3PBL) [27] . All the alignments were generated using Modeller 9.10, using default settings that were manually modified afterwards with careful attention to the alignment of all the conserved residues. The 'Biopolymer structure preparation' protocol of Sybyl 7.5 was used to prepare the models, and the minimization tool of Sybyl 7.5 was used to minimize all the models stepwise from hydrogen side-chains and mainchains to whole molecule minimization. The dopamine D 1 receptor models were later subjected to molecular dynamics (MD) simulation using Gromacs 4.5 for further refinement of the long ECL2. The MD simulation was performed for 40 ns using the CHARMM27 force field, and all the heavy atoms, except those on ECL2, were restrained by a constant force of 100 000 (kJ·mol -1 ·nm -2 ). The production runs were conducted using NTP ensemble at 300K, with a 1 fs time-step integration. The Particle Mesh Ewald method (PME) was used to calculate the electrostatic contribution to non-bonded interactions, with a cutoff of 9 Å and a time step of 1 fs. The cutoff distance of the van der Waals interaction and coulomb interaction were 14 Å and 9 Å, respectively. The LINCS algorithm was applied to the system. All the models were evaluated and validated using PROCHECK and the Pro-SA web server. Autodock 4.2 was used to search for the binding conformation of compound 1 and SKF38393 in the A 1 receptor and D 1 receptor, respectively. A binding box of 19×19×22 Å, centered at the binding cavity, was used, and 100 conformations were generated for each ligand using genetic algorithm. The binding conformation was chosen from the largest cluster (cluster tolerance was determined using default settings) and validated with the available mutation experiment data.
The ZDOCK protocol in Discovery studio 2.5 suite was used to search the heterodimer interface. Default parameters were used, and the results were selected manually. The PEG linker was added to the heterodimer and minimized using Sybyl 7.5.
Results
Chemistry
The bivalent ligands, 20a-20b, and monovalent ligands, 21a-21b, were designed and synthesized through the route outlined in Scheme 1. All the compounds were purified by silica gel thin-layer chromatography (>95%), and their structures were determined by nuclear magnetic resonance spectra and low-resolution mass spectra. Details of their structures are shown in Table 2 .
Receptor binding assay The binding affinity assay was performed using the bivalent ligands, 20a-20b, with 4 and 6 polyethylene glycol units, respectively, along with their monovalent ligands, 21a-21b. As expected, the bivalent ligands, 20a-20b, showed moderate binding for the A 1 receptor and D 1 receptor, while the monovalent control ligands, 21a-21b, showed moderate binding for the A 1 receptor. However, there was no correlation between linker length and binding affinity for the bivalent ligands, 20a-20b. It is possible that the high flexibility of the PEG linker could explain this phenomenon. The affinities for A 1 R was 10-100 times higher for bivalent ligands compared with their monovalent controls. These results are summarized in Table 2 . heterodimer interface was searched by ZDOCK and checked manually based on the ZDOCK score and associated bioinformatics data. Tarakanov and Fuxe deduced a set of triplets that may be responsible for receptor-receptor interactions [28, 29] . Leucine-rich motifs, one type of these triplets, are charged residues that may serve as an 'adhesive guide' for the formation of strong bonds between the amino acids of two receptors. As seen in Figure 3 , the homology triplets, ILS and AAV, exist in helix 4 of A 1 and helix 1 of D 1 . Combined with the docking rank, we established a heterodimer model with the interface of helixes 3, 4, and 5 of the A 1 receptor and helixes 1, 6, and 7 from the D 1 receptor (Figure 4) . The distance between the two ligand binding sites in this heterodimer model is approximately 48.4 Å, which is shorter than the length of the bivalent ligands. The linker of 20b was manually added to the docked ligands in the heterodimer model and minimized with Sybyl tools. As shown in Figure 4 , the linker tightly interacts with ECL2 and ECL1 of the A 1 receptor and D 1 receptor. Moreover, 
Discussion
According to the binding assay results shown in [9, 30] . These data indicate the specific interaction of these bivalent ligands with A 1 -D 1 receptor heteromers and suggest that these ligands could be useful as pharmacological tools to detect receptor heteromers in native tissue.
FRET technology has been decisive for demonstrating heteromer formation in heterologous expression systems. This study employed FRET technology to screen for bivalent ligands that promote the formation of A 1 R and D 1 R heterodimers. FRET efficiency values obtained from cells co-transfected with A 1 YFP/D 1 CFP differed significantly compared to those of the negative control group. Similar significant differences were also observed in the FRET efficiency values of cells treated with bivalent ligands compared to the negative control cells. These results confirm that bivalent ligands can detect the presence of heterodimers of A 1 R and D 1 R.
The docking experiments showed that the linker of the bivalent ligands is long enough to allow for the two pharmacophoric moieties to bind an A 1 -D 1 heterodimer. The minimum distance between the two ligand binding sites in this heterodimer model was 48.4 Å. This length is similar to the one proposed for other GPCR dimers, such as A 2A -D 2 receptor heterodimers. As shown in Figure 4 , the linker has a tight interaction with ECL2 and ECL1 of the A 1 and D 1 receptors. Moreover, the oxygen atoms on the PEG linker form polar interactions with the polar residues on the extracellular loops of the heterodimer, which enhances the binding ability of the bivalent ligand to the heterodimer. Ligand docking studies verify that bivalent ligands bind to both binding sites in the heterodimer.
Conclusion
This report provides evidence for the existence of A 1 R and D 1 R heteromers. However, in native tissues, there is no direct evidence to prove the existence of A 1 -D 1 receptor heterodimerization. In the present study, we designed and synthesized a 
To a solution of Compound 5 (600 mg, 1.32 mmol) in methanol (120 mL) stirred at rt, was added 20% NaOH (11 mL). The reaction mixture was stirred at 60 o C for 3 h. After cooling the reac- 
To a solution of compound 6 (100 mg, 0.25 mmol) and 3a (60 mg, 0.28 mmol) in dry DMF (10 mL) stirred at rt, were added PyBOP (143 mg, 0.28 mmol), DIPEA (88 μL, 0.5 mmol), the reaction mixture was stirred at rt overnight. The solvent was evaporated, the residue was purified by chromatography (10: 1 DCM-MeOH) to afford the title compound as a white solid (96 mg, 60% 
2-bromo-1-(4-nitrophenyl)ethanone (8)
To a solution of 4-nitroacetophenone (30 g, 0.18 mol) in dry ether (500 mL) stirred at 0 o C, was added AlCl 3 (cat), followed by Br 2 (10.3 mL, 0.20 mol). The reaction mixture was stirred at rt fot 3 h. Then the reaction was quenched with Na 2 S 2 O 3 -NaHCO 3 (aq), extracted with DCM (400 mL*2), the combined organic phase was washed with brine, dried over Na 2 SO 4 , filtered and concentrated to give the title compound as yellow solid (42 
2-(4-nitrophenyl)oxirane (9)
To a solution of compound 8 (43 g, 0.18 mol) in 150 mL CH 3 OH-THF (V/V=1/1.2) stirred at 0 o C, was added NaBH 4 (6.8 g, 0.18 mol), followed by 2 mol/L NaOH (90 mL). The reaction mixture was stirred at rt for 35 min. The solvent was evaporated under vacuum, the residue was treated with HOAc to adjust pH=4, extracted with DCM (100 mL), the organic phase was washed with saturated NaHCO 3 , water and brine, dried over Na 2 SO 4 , filtered and concentrated. The crude product was then purified by chromatography ( 
2-(3,4-dimethoxyphenethylamino)-1-(4-nitrophenyl)ethanol (10)
To a solution of 9 (5 g, 0.03 mol) in dry THF (50 mL) stirred under N 2 at rt, was added 3,4-dimethoxyphenethylamine (5.6 mL, 0.033 mol), the reaction mixture was heated to reflux overnight. The solvent was evaporated under vacuum, and the residue was purified by chromatography (10:1 DCM-MeOH) to give the title compound as an a yellow solid (18 g, 56%); 1 H-NMR (300 MHz, 
Compound 10 (10 g, 0.029 mmol) was treated with PPA (80 mL), the reaction was heated to 100 o C for 1.5 h. After cooling the reaction, the solution was poured into ice water, basidified by ammonia to adjust the pH>9, extracted with DCM (200 mL*2). The combined organic phase was washed with water and brine, dried over Na 2 SO 4 , filtered and concentrated to give the title compound as a red solid (11.3 To a solution of 13 (5 g, 7.48 mmol), triphenyl phosphine (4.56 g, 14.9 mmol) and hex-5-yn-1-ol (1.65 mL, 14.9 mmol) in dry DCM (30 mL) To a solution of compound 18a (45 mg, 0.03 mmol) and K 2 CO 3 (40 mg, 0.3 mmol) in dry DMF (10 mL) stirred at rt, was added PhSH (30 μL, 0.3 mmol), the reaction mixture was stirred at rt overnight. The solvent was evaporated under vacuo, the residue was purified by silica gel thin-layer chromatography (9:1 DCM-MeOH) to afford the title compound as a yellow solid (20 To a solution of compound 19a (12 mg, 0.01 mmol) in DCM (4 mL) stirred at rt, was added TFA (1 mL), the reaction mixture was stirred at rt for 30 min. The solvent was evaporated under vacuo, the residue was purified by silica gel thin-layer chromatography (9:1 DCM-MeOH) to afford the title compound as an amorphous white solid (6.5 mg, 60% 
